Preclinical studies demonstrated the binding of MDX-H210 to FcγRI on G-CSF-primed PMN and to HER-2/neu on SK-BR-3 breast carcinoma cells to be comparable to the respective parental mAb. This evidence concerns the gene ERBB2 and breast carcinoma.